Bradford, RI, United States of America

Joseph Kushner, Iv

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2018-2022

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Joseph Kushner, IV: Innovator in Pharmaceutical Formulations

Introduction

Joseph Kushner, IV, a prominent inventor based in Bradford, RI, has made significant contributions to the field of pharmaceuticals. With three patents to his name, his work primarily focuses on innovative dosage forms that enhance the efficacy of medications.

Latest Patents

Among Kushner's most notable inventions are his patents related to oral sustained release formulations of tofacitinib. These formulations, which include pharmaceutical acceptable salts, exhibit desirable pharmacokinetic characteristics, optimizing the therapeutic effects of the compound. His research emphasizes not only the effectiveness of the drug but also its reliability and consistency in patient treatment.

Career Highlights

Kushner's professional journey is marked by his association with Pfizer Corporation, a leading global biopharmaceutical company. His role at Pfizer has allowed him to delve into complex pharmaceutical challenges, contributing to the advancement of drug formulations that improve patient outcomes.

Collaborations

Throughout his career, Kushner has collaborated with talented colleagues, including Scott Max Herbig and Sriram Krishnaswami. These partnerships have fostered an environment of innovation, leading to significant advancements in pharmaceutical research and development.

Conclusion

Joseph Kushner, IV stands out as a dedicated inventor whose work in oral sustained release formulations of tofacitinib has the potential to transform patient care. His contributions reflect the ongoing pursuit of innovation in the pharmaceutical industry, aiming to deliver better therapeutic options for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…